Bellerophon Therapeutics Inc (NASDAQ:BLPH)’s share price traded up 5.6% during mid-day trading on Friday . The stock traded as high as $0.39 and last traded at $0.38, 165,100 shares were traded during trading. A decline of 33% from the average session volume of 245,033 shares. The stock had previously closed at $0.36.
Several research analysts recently issued reports on the company. ValuEngine downgraded Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Maxim Group restated a “buy” rating and set a $2.00 price objective on shares of Bellerophon Therapeutics in a research report on Thursday, November 7th.
The stock has a market capitalization of $26.35 million, a PE ratio of -1.12 and a beta of -0.05. The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.25. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.58.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. As a group, analysts predict that Bellerophon Therapeutics Inc will post -0.23 EPS for the current year.
In other Bellerophon Therapeutics news, major shareholder Associates Iv L. P. Venrock sold 704,595 shares of Bellerophon Therapeutics stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $0.50, for a total value of $352,297.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Associates Iv L. P. Venrock sold 333,010 shares of Bellerophon Therapeutics stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $0.44, for a total transaction of $146,524.40. The disclosure for this sale can be found here. 53.10% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in BLPH. LPL Financial LLC grew its stake in shares of Bellerophon Therapeutics by 22.1% during the 2nd quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 23,650 shares during the period. Vanguard Group Inc. grew its stake in shares of Bellerophon Therapeutics by 15.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock valued at $690,000 after buying an additional 158,000 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Bellerophon Therapeutics by 8.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock valued at $860,000 after buying an additional 116,862 shares during the period. 53.35% of the stock is owned by hedge funds and other institutional investors.
Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
Further Reading: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.